Cadherin-17 (CDH17) Cancer Target
CDH17 is an adhesion molecule from the cadherins family and assumes a significant role during embryogenesis and for maintenance of water-tight junctions in gastrointestinal tract.
Our founder/CEO Dr John Luk identified and patented CDH17 as a therapeutic cancer target, where aberrant expressions of CDH17 is closely associated with the development, progression and metastasis of various GI cancers.
TriAx multispecific antibody platform
Arbele’s proprietary multispecific antibody platform is designed for greater efficacy in GI cancer treatment through the combination of multiple anti-tumor mechanisms. Arbele has developed a family of multispecific antibodies, based around two novel core structures. These ‘TriAx’ antibodies are designed for low antigenicity, stability, and desirable bio distribution and pharmacokinetic properties. Anti-tumor mechanisms incorporated into TriAx antibodies includes redirection of T/NK cell cytotoxicity, inhibition of immune check points, phagocytosis and enhancement of an adaptive immune response.
Antibody drug conjugate
ADCs are developed from our proprietary library of >300 anti-CDH17 monoclonal antibodies. The ADCs are designed to deliver cytotoxic drugs to CDH17-overexpressing tumors, thereby maximizing the killing effect and at the same time reducing the adverse effects on normal tissues. One of the lead molecules utilize a novel anti-tumor MOA depending on the cytotoxic property of the conjugated photosensitizer upon photoactivation. This system offers an effective treatment with additional safety benefits.
Arbele has developed its proprietary technology mainly around two platforms: next-generation chimeric antigen receptor T (CAR-T) cells and multi-specific T-cell engaging antibodies. To effectively address formidable pro-tumor mechanisms within a solid tumor microenvironment (TME), Arbele’s non-viral CAR vectors are engineered for multiple anti-tumor CAR cell activities such as targeting more than one tumor antigen, reversal of tumor immunosuppression and the recruitment and activation of additional effector cell types and cytotoxic activities. Certain vector genes are engineered to be expressed only in response to the local tumor microenvironment to ensure greater safety and efficacy. These otherwise quiescent CAR cells are stimulated by tumor cells or other components of the TME to generate an artificially enhanced immune response and thus function as artificial immunosurveillance CAR cells or “AI-CAR”.
Tiberias Technology, one of the subsidiaries of Arbele, is dedicated to pioneering advancements in the field of in vitro diagnostics (IVD) specifically tailored for the prevention, detection, and management of GI cancers.
Our comprehensive array of cutting-edge solutions encompasses blood and tissue diagnostics, alongside efficient point-of-care tests. These innovations collectively cover every crucial juncture of the patient’s journey – from the initial phases of early cancer detection through to precise diagnostic procedures, personalized treatment strategizing, vigilant monitoring, and even post-treatment surveillance.
Tiberias Technology endeavors to enhance the landscape of GI cancer care, ultimately contributing to improved patient outcomes and a higher standard of healthcare.
Copyright©2023 Arbele All Rights Reserved.